Indicated in Brazil only for people with non-Hodgkin lymphoma, acute lymphoblastic leukemia, and multiple myeloma who failed conventional therapies such as chemotherapy or had relapsed the disease, CAR-T therapy can revolutionize onco-hematological treatment and change the prognosis of patients.
After all, lymphomas alone, a type of blood cancer that affects immune cells, are responsible for 5,000 people in Brazil every year, according to data from the National Cancer Institute (INCA). Every year, more than 15,000 new cases of the disease are registered in the country, whose incidence has doubled in the last 20 years.
CAR-T therapy for the treatment of lymphomas is one of the topics of the 14th Brazilian Lymphoma Conference (BLC 2024), the Brazilian Lymphoma Conference, which will take place virtually from next Wednesday (24) to Saturday (27). The largest lymphoma event in Latin America, BLC 2024 brings together doctors, researchers and medical students from Brazil and other countries and brings the main international updates in the area.
Check out the program details and guarantee your free registration by clicking here
However, according to Dr. Carlos Chiattone, president of BLC 2024, the speakers will not only bring the most recent scientific content on lymphomas, but will also show a critical view regarding the applicability of new cancer treatments, such as CAR-T therapy, in countries with less financial resources such as Brazil.
“In 2023, the National Cancer Prevention and Control Policy was sanctioned under the Unified Health System. One of the topics is cancer funding in Brazil, which is an aspect that we are going to consider in BLC 2024 in the problematization of new technologies for the diagnosis and treatment of cancer,” says Chiattone, who is also director of Institutional Relations of the Brazilian Association of Hematology, Hemotherapy and Cell Therapy (ABHH), the scientific society that promotes the event.
Schedule — BLC 2024 will be attended by speakers from Brazil and the United States, Switzerland, Portugal, Italy and Germany. Among the main topics of the event are updates on epidemiology, molecular biology, clinical studies, diagnosis and treatment for different types of lymphomas, and access to new therapies.
Highlights, on Wednesday (24), are the class on “R/R Diffuse Large B Cell Lymphoma: Why think about CAR-T Therapy?”. On Thursday (25), classes on “Game of Thrones in chronic lymphocytic leukemia: which first-line therapy will survive?” , “New clinical and biological prognostic factors” and “adult T-cell leukemia/lymphoma: Data from the T-cell Brazil Project”.
On Friday (26), the joint session of the BLC with the Latin American Lymphoproliferative Study Group (GELL) “Understanding our common problems” and the classes “How to bring more clinical studies to Latin America?” and “Access to new therapies for onco-hematological diseases”. On Saturday (27), the lecture “Circulating Tumor DNA in Lymphoma: Principles and Future Directions” will take place with Ash A. Alizadeh, renowned specialist from Stanford University.
It is also worth noting the class 'Onco-hematological Diseases in Brazilian Amerindians', which is part of the purpose of BLC 2024 to think about equity in access to new technologies in the country. After all, it is necessary to look at the population and understand the demands of different groups such as indigenous people.
O BLC 2024 there will be simultaneous translation and registrations for participants can be made on the site: https://abhheventos.com.br/blc2024/
The event will take place in a virtual format from April 24 to 27.
